+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of azithromycin mass drug administration MDA on child survival and antimicrobial resistance AMR in Niger. This adaptive platform trial focuses on monitoring under-5 mortality rates and AMR as the azithromycin program expands nationwide. The study aims to track mortality trends over time relative to global reduction targets and to assess the ongoing effectiveness and risks associated with azithromycin use in children. Participants receive azithromycin distribution targeted to children aged 1 to 59 months, delivered door-to-door by community health workers. The study compares three groups continuous azithromycin distribution for four years, delayed distribution beginning after two years, and stopping distribution after two years. This design includes monitoring and re-randomization every two years to adapt the intervention based on observed outcomes. During the study, participants undergo surveillance for mortality and AMR through nasopharyngeal and rectal swabs collected at two- and four-year intervals. Researchers measure all-cause mortality, prevalence of macrolide resistance, genetic resistance markers, and frequency of infectious clinic visits. The trial includes verbal approvals from communities and caregivers, and tracks program costs and reported illnesses over time, with a total duration extending to four years of treatment and monitoring.

Age: 1Month - 59MonthsAll GendersPhase 4
1 location
R

Actively Recruiting

This registry collects detailed information about children diagnosed with cancer who are treated in pediatric oncology units affiliated with the French African Oncology Group in French-speaking Africa. Its goal is to gather data on patient numbers, cancer stage, treatments received, and outcomes to support better planning and delivery of pediatric oncology care in the region. The registry aims to provide valuable insights for local and national health authorities to improve pediatric cancer programs. Children and adolescents under 18 years old who present at participating pediatric oncology units and have any type of cancer are included in this observational registry. Data collected includes demographic information, socioeconomic status, clinical details, treatment status, vital status, treatment abandonment, and loss to follow-up. The information is entered online using the REDCap system and securely stored by the IT department at Gustave ROUSSY in Paris. Participants information is gathered continuously during their treatment and follow-up at the hospital units. The main measures tracked include the number of children suspected of having cancer within 12-month periods, their vital status, illness status, and treatment status. This ongoing data collection helps monitor outcomes and supports healthcare planning. Participation involves no experimental treatment and is focused on data recording and observation over time.

Age: 1Day - 18YearsAll Genders
14 locations
T

Actively Recruiting

This research aims to evaluate whether a high-dose first-line treatment is as safe as the standard dosing for patients previously treated for rifampicin-susceptible recurrent Tuberculosis TB. This randomized clinical trial includes people with recurrent pulmonary TB to compare two regimens, focusing on safety and effectiveness in preventing resistance and relapse over time. The study has two stages Stage 1 compares a standard 6-month regimen 6EHRZ with a high-dose regimen 6EHRZ that uses triple doses of rifampicin and isoniazid alongside pyrazinamide and ethambutol. If the high-dose regimen is not found non-inferior, the study continues with the standard regimen and an adapted intervention. Stage 2 shifts to an observational cohort using only the standard regimen due to safety concerns. Patients receive daily treatment under supervision with monthly clinic visits and liver function tests at set intervals. Participants are closely monitored during and after treatment, including regular checks for adverse effects, treatment response, and TB relapse through sputum tests at six months and one year post-treatment. Researchers track safety outcomes such as serious adverse events and liver toxicity, as well as bacterial effectiveness and resistance development, with follow-up lasting up to 18 months.

All AgesAll GendersPhase 3
1 location